These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 22333403)

  • 1. Improvement in renal function after everolimus introduction and calcineurin inhibitor reduction in maintenance thoracic transplant recipients: the significance of baseline glomerular filtration rate.
    Arora S; Gude E; Sigurdardottir V; Mortensen SA; Eiskjær H; Riise G; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Aukrust P; Solbu D; Iversen M; Gullestad L
    J Heart Lung Transplant; 2012 Mar; 31(3):259-65. PubMed ID: 22333403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
    Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients.
    Kaplinsky E; González-Costello J; Manito N; Roca J; Barbosa MJ; Nebot M; Salazar-Mendiguchia J; Berdejo J; Mañas P; Miralles A; Cequier A
    Transplant Proc; 2012 Nov; 44(9):2564-6. PubMed ID: 23146455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
    Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation.
    Gude E; Gullestad L; Arora S; Simonsen S; Hoel I; Hartmann A; Holdaas H; Fiane AE; Geiran OR; Andreassen AK
    J Heart Lung Transplant; 2010 Jun; 29(6):641-7. PubMed ID: 20304681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of long-term renal function after conversion to proliferation signal inhibitors in long-term heart transplant recipients.
    González-Vilchez F; de Prada JA; Castrillo C; Canteli A; Llano MF; Martín-Durán R
    J Heart Lung Transplant; 2011 May; 30(5):552-7. PubMed ID: 21212001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
    Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
    J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial.
    Gullestad L; Mortensen SA; Eiskjær H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Iversen M
    Transplantation; 2010 Dec; 90(12):1581-9. PubMed ID: 21030905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F
    Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
    Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
    J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series.
    Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J
    Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) after heart transplantation: 2 years' follow-up from the University Hospital Münster.
    Stypmann J; Engelen MA; Eckernkemper S; Amler S; Gunia S; Sindermann JR; Rothenburger M; Rukosujew A; Drees G; Welp HA
    Transplant Proc; 2011 Jun; 43(5):1847-52. PubMed ID: 21693288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels.
    Gustafsson F; Gude E; Sigurdardottir V; Aukrust P; Solbu D; Goetze JP; Gullestad L
    Biomark Med; 2014; 8(2):239-45. PubMed ID: 24521021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective 12-month study of conversion to everolimus in lung transplant recipients.
    Roman A; Ussetti P; Zurbano F; Borro JM; Solé A; Carreño MC; Santos F
    Transplant Proc; 2011 Sep; 43(7):2693-8. PubMed ID: 21911148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes of thoracic transplant recipients following conversion to everolimus with reduced calcineurin inhibitor in a multicenter, open-label, randomized trial.
    Gullestad L; Eiskjaer H; Gustafsson F; Riise GC; Karason K; Dellgren G; Rådegran G; Hansson L; Gude E; Bjørtuft Ø; Jansson K; Schultz HH; Solbu D; Iversen M
    Transpl Int; 2016 Jul; 29(7):819-29. PubMed ID: 27067532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
    Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: results from a randomized trial in kidney transplantation.
    Mjörnstedt L; Schwartz Sørensen S; von Zur Mühlen B; Jespersen B; Hansen JM; Bistrup C; Andersson H; Gustafsson B; Solbu D; Holdaas H
    Transpl Int; 2015 Jan; 28(1):42-51. PubMed ID: 25176389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.